De novo design of miniproteins targeting GPCRs

AI Insight

Researchers report the computational de novo design of miniproteins engineered to bind specifically to G protein-coupled receptors (GPCRs), a large and therapeutically important class of membrane proteins. Using structure-based design principles, the team generated small protein scaffolds capable of engaging GPCR binding sites with high selectivity. The work demonstrates that artificial miniproteins can be rationally constructed to interact with targets that have historically been difficult to address with protein-based tools.

Why it matters

GPCRs represent the target of approximately 35 percent of all approved drugs, and the ability to design custom protein binders against them could open new avenues for highly selective therapeutics and research tools. This approach may eventually enable the development of novel drug candidates with improved specificity compared to small molecules currently used to modulate GPCR activity.